Proportion of single-chain recombinant tissue plasminogen activator and outcome after stroke.
Fiche publication
Date publication
décembre 2016
Journal
Neurology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr MOULIN Thierry
Tous les auteurs :
Leys D, Hommet Y, Jacquet C, Moulin S, Sibon I, Mas JL, Moulin T, Giroud M, Sagnier S, Cordonnier C, Medeiros de Bustos E, Turc G, Ronzière T, Bejot Y, Detante O, Ouk T, Mendyk AM, Favrole P, Zuber M, Triquenot-Bagan A, Ozkul-Wermester O, Montoro FM, Lamy C, Faivre A, Lebouvier L, Potey C, Poli M, Hénon H, Renou P, Dequatre-Ponchelle N, Bodenant M, Debruxelles S, Rossi C, Bordet R, Vivien D,
Lien Pubmed
Résumé
To determine whether the ratio single chain (sc)/(sc + 2 chain [tc]) recombinant tissue plasminogen activator (rtPA) influences outcomes in patients with cerebral ischemia.
Mots clés
Aged, Aged, 80 and over, Brain Ischemia, complications, Cerebral Hemorrhage, complications, Disability Evaluation, Female, Fibrinolytic Agents, chemistry, Humans, Male, Middle Aged, Recombinant Proteins, chemistry, Seizures, complications, Severity of Illness Index, Stroke, complications, Thrombolytic Therapy, Time-to-Treatment, Tissue Plasminogen Activator, chemistry, Treatment Outcome
Référence
Neurology. 2016 Dec 6;87(23):2416-2426